Tyrosine Kinase Inhibitors Could Be Effective Against Non-small Cell Lung Cancer Brain Metastases Harboring Uncommon EGFR Mutations

Eitemau Tebyg

• Afatinib for Advanced Non-small Cell Lung Cancer in a Case With an Uncommon Epidermal Growth Factor Receptor Mutation (G719A) Identified in the Cerebrospinal Fluid
  gan: Ma, Chunhua, et al.
  Cyhoeddwyd: (2019)
• Corrigendum: Afatinib for Advanced Non-small Cell Lung Cancer in a Case With an Uncommon Epidermal Growth Factor Receptor Mutation (G719A) Identified in the Cerebrospinal Fluid
  gan: Ma, Chunhua, et al.
  Cyhoeddwyd: (2019)
• Effective Treatment With Afatinib of Lung Adenocarcinoma With Leptomeningeal Metastasis Harboring the Exon 18 p.G719A Mutation in the EGFR Gene Was Detected in Cerebrospinal Fluid: A Case Report
  gan: Ma, Chunhua, et al.
  Cyhoeddwyd: (2020)
• Patients harboring EGFR mutation after primary resistance to crizotinib and response to EGFR-tyrosine kinase inhibitor
  gan: Wang, Wenxian, et al.
  Cyhoeddwyd: (2016)
• Uncommon EGFR mutations in lung adenocarcinoma: features and response to tyrosine kinase inhibitors
  gan: Brindel, Aurélien, et al.
  Cyhoeddwyd: (2020)